CLEOCIN Drug Patent Profile

When do Cleocin patents expire, and when can generic versions of Cleocin launch?

Cleocin is a drug marketed by Pharmacia And Upjohn and Pfizer and is included in fourteen NDAs.

The generic ingredient in CLEOCIN is clindamycin palmitate hydrochloride. There are fifty-five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the clindamycin palmitate hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cleocin

A generic version of CLEOCIN was approved as clindamycin palmitate hydrochloride by PADAGIS US on July 7^th, 2010.

Summary for CLEOCIN

US Patents:	0
Applicants:	2
NDAs:	14

US Patents and Regulatory Information for CLEOCIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmacia And Upjohn	CLEOCIN	clindamycin hydrochloride	CAPSULE;ORAL	061809-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Pfizer	CLEOCIN T	clindamycin phosphate	GEL;TOPICAL	050615-001	Jan 7, 1987	AB1	RX	Yes	Yes
Pfizer	CLEOCIN	clindamycin phosphate	SUPPOSITORY;VAGINAL	050767-001	Aug 13, 1999		RX	Yes	Yes
Pfizer	CLEOCIN	clindamycin phosphate	CREAM;VAGINAL	050680-002	Mar 2, 1998	AB	RX	Yes	Yes
Pfizer	CLEOCIN PHOSPHATE	clindamycin phosphate	INJECTABLE;INJECTION	062803-001	Oct 16, 1987	AP	RX	No	No
Pfizer	CLEOCIN T	clindamycin phosphate	SOLUTION;TOPICAL	050537-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

International Patents for CLEOCIN

See the table below for patents covering CLEOCIN around the world.

Country	Patent Number	Title	Estimated Expiration
Morocco	26749
Portugal	1200065
European Patent Office	1200065	COMPOSITION D'OVULE CLINDAMYCINE INTRAVAGINALE (INTRAVAGINAL CLINDAMYCIN OVULE COMPOSITION)
Spain	2207532
Australia	768907
Honduras	2000000166	COMPOSICION DE OVULOS INTRAVAGINALES DE CLINDAMICINA

Supplementary Protection Certificates for CLEOCIN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1304992	PA2013025,C1304992	Lithuania		PRODUCT NAME: CLINDAMYCINUM + TRETINOINUM; REGISTRATION NO/DATE: LT/1/13/3279/001, 2013 04 26 LT/1/13/3279/002, 2013 04 26 PA1332/043/001 20130323
1304992	2013C/060	Belgium		PRODUCT NAME: CLINDAMYCINE (ALS CLINDAMYCINE FOSFAAT) EN TRETINOINE; AUTHORISATION NUMBER AND DATE: BE437507 20130506
1304992	CR 2013 00053	Denmark		PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
1304992	2013/044	Ireland		PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
1304992	C300617	Netherlands		PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
1304992	122013000081	Germany		PRODUCT NAME: CLINDAMYCIN (ALS CLINDAMYCIN-PHOSPHAT) UND TRETINOIN; NAT. REGISTRATION NO/DATE: 85210.00.00 20130611; FIRST REGISTRATION: IRLAND PA1332/043/001 20130322

Analysis of the Investment Scenario, Market Dynamics, and Financial Trajectory for CLEOCIN (Clindamycin)

Last updated: February 3, 2026

---

Summary

CLEOCIN, the brand name for Clindamycin, is a widely prescribed antibiotic indicated primarily for bacterial infections. This analysis evaluates CLEOCIN’s investment potential by examining current market dynamics, competitive landscape, regulatory considerations, and financial projections. The report highlights key factors influencing growth, including increasing antibiotic resistance, regulatory trends, patent status, and emerging markets. The analysis concludes with strategic insights tailored for investors seeking to navigate CLEOCIN’s market trajectory.

---

1. Overview of CLEOCIN and Its Market Position

Attribute	Details
Active Ingredient	Clindamycin hydrochloride
Therapeutic Class	Lincosamide antibiotic
Indications	Bacterial skin infections, respiratory tract infections, septicemia, odontogenic infections
Administration Routes	Oral, intravenous, topical
Patent Status	Generic formulations dominate; original patents expired circa 2002-2003
Key Manufacturers	Pfizer (original), generic manufacturers worldwide

Market Share & Revenue
Though precise revenue numbers are proprietary, estimates suggest global sales of Clindamycin formulations ranged between $250 million and $350 million annually (pre-pandemic levels). The drug’s usage is declining in some regions owing to resistance but remains significant where bacterial resistance is manageable.

---

2. Investment Scenarios: Market Demand and Growth Drivers

A. Increasing Antibiotic Resistance

Trend	Impact on CLEOCIN
Rise in resistant bacteria	Limits efficacy, may reduce sales unless formulations or indications expand
Development of resistant strains (e.g., MRSA)	Adds new clinical value for certain infections, possibly sustaining demand
Regulatory pressure	Encourages stewardship programs, potentially restricting broad use

B. Regulatory and Policy Environment

Region	Key Policies	Impact
U.S.	FDA guidelines on antimicrobial stewardship	May restrict off-label use, impacting sales
Europe	EMA antimicrobial resistance initiatives	Increased scrutiny may affect prescribing habits
Emerging Markets	Less restrictive, higher growth potential	Increased access could expand market size

C. Competitive Landscape

Participants	Market Share & Strategies
Patent Status	Multiple generics significantly reduce pricing power
New Antibiotics	Emergence of novel agents (e.g., dalbavancin) may overshadow CLEOCIN
Delivery Innovations	Liposomal formulations or combination therapies could affect positioning

D. Emerging Indications & Formulation Advances

Innovation	Potential	Investment Impact
Topical formulations	Expanding use in skin infections	Moderate, with niche focus
Combination therapies	Treat resistant strains	High potential if cleared by regulations
New delivery systems	Improved bioavailability or compliance	Investment in R&D needed

---

3. Financial Trajectory and Market Dynamics

Projection Year	Global Sales (USD millions)	Growth Rate (%)	Key Drivers
2023	250	-3 to 0	Market saturation, resistance issues
2025	230	-2	Ongoing resistance, generics competitiveness
2027	210	-1	Potential expansion in emerging markets
2030	190	-1	Market maturation, new formulations or indications

Note: The slight decline reflects resistance trends and generic price erosion, stabilized by potential new indications and emerging markets.

Cost Structure & Margins:

• Manufacturing Costs: Estimated at 15-20% of revenue for generics.
• Pricing Strategy: Highly price-sensitive due to commoditization.
• Profit Margins: Estimated at 10-15%, influenced by market competition and regulatory costs.

---

4. SWOT Analysis

Strengths	Weaknesses	Opportunities	Threats
Established efficacy	Patent expiry reduces exclusivity	Emerging markets with growing antibiotic demand	Rise of antibiotic resistance
Wide clinical acceptance	High generic competition	Development of novel formulations	Regulatory restrictions
Broad spectrum efficacy	Declining premier status	Strategic partnerships for formulations	Competing novel antibiotics

---

5. Comparative Market Analysis: CLEOCIN vs. Alternatives

Parameter	CLEOCIN (Clindamycin)	Alternative Agents	Implication
Spectrum	Aerobic Gram-positive, anaerobic	Daptomycin, linezolid	Niche positioning remains essential
Resistance Profile	Growing resistance in some pathogens	Less resistance with newer agents	Market share may decline unless resistance addressed
Pricing	Low (generic)	Higher	Price competition pressures profitability
Side Effects	Gastrointestinal, C. difficile risk	Similar or newer with better tolerability	Clinical and marketing considerations

---

6. Regulatory Considerations and Future Outlook

Frameworks & Policies	Implication for Investment
US FDA Antimicrobial Stewardship	May restrict off-label use; necessitate targeted indications
EU Antibiotic Policies	Emphasis on responsible use; impact on sales volume
WHO Guidelines	Drive clinical protocols; can influence prescribing habits

Future Regulatory Trends

• Emphasis on stewardship, which could favor targeted high-grade formulations.
• Accelerated approvals for new formulations or combination therapies in resistant infections.

---

7. Key Drivers for Investment and Strategic Considerations

Driver	Details	Investment Implication
Market Demand	Persistent need in resistant infections	Steady cash flow if market maintained
R&D Innovation	Formulations, combinations	Significant investment, high-risk
Emerging Markets	Untapped growth potential	High reward, differential risk
Regulatory Environment	Stringent controls	Monitor to avoid compliance risks

---

8. Conclusion: Projected Financial Trajectory and Investment Viability

Summary	Details
Market Stability	Marginal decline expected, balancing generic competition and resistance
Growth Opportunities	Emerging markets, formulation innovations, niche indications
Investment Risks	Resistance, regulatory restrictions, competitive dynamics
Entry Strategy	Focus on niche indications, partnerships in emerging markets, R&D for formulations

---

Key Takeaways

• Market Saturation & Competition: Market for CLEOCIN (Clindamycin) is mature with high generic penetration and price competition, leading to flat or declining revenues.
• Resistance & Stewardship: Rising bacterial resistance and global stewardship policies may constrain use but also open niche opportunities in resistant infections.
• Emerging Market Expansion: Untapped growth segments in low- and middle-income countries with less restrictive regulation.
• Innovation Potential: Formulation improvements, combination therapies, and targeted indications could provide short-term growth.
• Regulatory Environment: Vigilance needed; policies can impact prescribing patterns, especially in the US and EU.

---

FAQs

1. What is the current patent status of CLEOCIN?
Clindamycin patents expired in the early 2000s, leading to widespread generic production worldwide, limiting pricing power but maintaining market accessibility.

2. How does bacterial resistance affect CLEOCIN’s market?
Resistance, especially among MRSA strains, has curtailed broad-spectrum use in some regions, though it retains value against susceptible strains, especially with newer formulations.

3. Are there upcoming formulations or combinations that could boost CLEOCIN's sales?
Potential exists in topical formulations, liposomal delivery systems, and combination therapies targeting resistant bacteria, but approval pathways are complex.

4. Which geographical markets offer the most growth potential for CLEOCIN?
Emerging markets in Asia, Africa, and Latin America display higher growth potential due to increasing antibiotic access and lower regulatory restrictions.

5. What are the primary risks to investing in CLEOCIN?
Key risks include declining efficacy due to resistance, regulatory restrictions, high generic competition, and the advent of newer antibiotics.

---

References

[1] MarketResearch.com, “Global Antibiotics Market Analysis,” 2021
[2] FDA Antimicrobial Resistance Policies, 2022
[3] WHO Antibiotic Resistance Strategic Framework, 2020
[4] Pfizer Annual Report, 2022
[5] European Medicines Agency, “Guidelines on the use of antibiotics,” 2021